米托蒽醌
米托蒽醌 性质
| 熔点 | 170-1740C |
|---|---|
| 沸点 | 554.47°C (rough estimate) |
| 密度 | 1.3049 (rough estimate) |
| 折射率 | 1.6500 (estimate) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | DMSO（少量）、甲醇（少量）、水（少量） |
| 酸度系数(pKa) | pKa 5.99 (Uncertain);8.13 (Uncertain) |
| 形态 | 固体 |
| 颜色 | 深蓝色到黑色 |
| CAS 数据库 | 65271-80-9(CAS DataBase Reference) |
| (IARC)致癌物分类 | 2B (Vol. 76) 2000 |
米托蒽醌 用途与合成方法
|
PKC 8.5 μM (IC 50 ) |
Topoisomerase II
|
Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 μg/mL) induces a decrease in cell viability. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC 50 values of 18 and 196 nM, respectively.
Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produces a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also shows effective antitumor activities and produces a 60% and a 45% ILS, respectively..
安全信息
| 危险品标志 | T,T+ |
|---|---|
| 危险类别码 | 46-61-26/27/28 |
| 安全说明 | 53-36/37/39-45-22 |
| WGK Germany | 3 |
| RTECS号 | CB5748500 |
| 海关编码 | 2922.50.2500 |
米托蒽醌 化学药品说明书
米托蒽醌 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-13502 | 米托蒽醌 | 65271-80-9 | 50mg | 515 |
| 2024-01-25 | HY-13502 | 米托蒽醌 | 65271-80-9 | 10mM * 1mLin DMSO | 567 |
